A double-blind, randomized controlled trial of Wharton's Jelly derived mesenchymal stem cells for treatment of acute myocardial infarction

Trial Profile

A double-blind, randomized controlled trial of Wharton's Jelly derived mesenchymal stem cells for treatment of acute myocardial infarction

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2015

At a glance

  • Drugs Umbilical cord mesenchymal stem cell therapy-Beike (Primary)
  • Indications Myocardial infarction
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Aug 2015 New trial record
    • 21 Jul 2015 Results published in the Media Release.
    • 21 Jul 2015 Primary endpoint (The absolute changes in myocardial viability and perfusion of the infarcted region from baseline to four months) has been met, according to a Beike Biotechnology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top